—Ana Ivonne Vazquez-Armendariz is setting out to develop “mini-organs” in order to study metabolic and disease mechanisms. She hopes that they can give her a better understanding of lung disease. As Argelander Professor in the Life and Health Transdisciplinary Research Area (TRA) at the University of Bonn, Vazquez-Armendariz is working at the interface between various disciplines, bridging the gap between chemistry, biology and medicine in the process.
T helper cells determine the course of disease in viral infections such as COVID-19
—People around the world have been infected with the SARS-CoV-2 virus for more than three years. It quickly became apparent that killer T cells play a crucial role in fighting the virus in the body by killing off infected cells. However, it was not entirely clear how the immune system manages to activate the defenses in a targeted manner and then calm them down again once the job is done. An international team, including ImmunoSensation² scientists, has now come a decisive step closer to understanding this phenomenon.
Expanding the partnership with Japan in science and research
—The Rector of the University of Bonn and ImmunoSensation² member, Prof. Dr. Dr. h.c. Michael Hoch, is currently traveling around Japan with a high-ranking delegation led by Hendrik Wüst, State Premier of North Rhine-Westphalia (NRW). One of the main purposes of the trip is to consolidate partnerships in science and research. The Rector is expected back in Bonn at the weekend with some signed cooperation agreements in his suitcase.
Two junior researchers invited to Lindauer Nobel Laureate Meetings 2023
—The two junior ImmunoSensation scientists Dr. Maike Effern and Dr. Susanna Ng from the Institute of Experimental Oncology at the University Hospital Bonn were invited to participate in this years Lindau Nobel Laureate Meetings. The annual conference in Lindau will take place from June 25th to 30th. The renowned conference is held for the 72nd time. The participants had to go through a lengthy application process in order to participate in the conference.
—Prof. Bernardo Franklin from the Institute of Innate Immunity at the University Hospital Bonn has been awarded a Proof of Concept Grant by the European Research Council (ERC) as part of a program designed to help researchers translate their ideas from previous ERC projects into commercial applications. The project entiteled “Nanobodies to prevent hematopoietic stem cell bias and hyper-inflammation” (UNBIAS), aims to “wipe” the immune system’s harmful memories of inflammation. The project is awarded with a funding of €150,000, provided over a period of around one year.
—An international research team, including ImmunoSensation² member Prof. Kathrin Leppek of the University Hospital Bonn and scientists from the German Center for Neurodegenerative Diseases (DZNE), the Netherlands, and the US has been awarded a US$ 1.3 million grant by the “Human Frontier Science Program” to investigate brain immune cells and manipulate them via light irradiation. This will involve using gene transcripts (mRNAs) as molecular mediators.
—Hannah Scheiblich and her group are investigating the role of microglia during neuroinflammation and their role in neurodegenerative diseases. Situated at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn, Scheiblich recently strted her research group at the cluster of excellence.
—Neurobiologist Özgün Gökce was recently recruited to the German Center of Neurodegenerative Diseasses (DZNE) on campus of at the University Hospital Bonn. He is also a member of the Medical Faculty at Bonn University. As head of the research group "Systems Neuroscience – Cell Diversity", Gökce has been appointed as a member of ImmunoSensation2 from March 2023.
Women TechEU Start-Up Funding for University of Bonn Spin-Off
—relios.vision GmbH, a University of Bonn start-up that has developed the SmartContrast software, receives funding from the European Innovation Council’s (EIC) Women TechEU program. ImmunoSensation² member Prof. Alexander Effland, together with experts from the fields of medicine and mathematics is involved in the company. Using artificial intelligence, SmartContrast aims to lower the use of contrast agents for magnetic resonance imaging of the brain, thus reducing examination costs and potential risks for patients and the environment.